Trial Profile
A retrospective study to evaluate the efficacy of sunitinib or sorafenib in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Sep 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 09 Sep 2015 New trial record
- 04 Sep 2015 Results published in Targeted Oncology.